



INTERNATIONAL APPLICATION PUBLISHED

(51) International Patent Classification ⁶ :

A61B 17/42, G01N 33/50, 33/53, 33/74

A1

WO 9603929A1

(43) International Publication Date: 15 February 1996 (15.02.96)

(21) International Application Number: PCT/US95/03442

(22) International Filing Date: 17 March 1995 (17.03.95)

(30) Priority Data:
08/285,796 4 August 1994 (04.08.94) US(71) Applicant: BIEK, INC. [US/US]; 885 Arapahoe Avenue,
Boulder, CO 80302 (US).(72) Inventor: DULLIEN, Vivian; 670 Emporia Road, Boulder, CO
80303 (US).(74) Agents: NEELEY, Richard, L. et al.; Cooley Godward Castro
Huddleson & Tatum, 4th floor, Five Palo Alto Square, Palo
Alto, CA 94306 (US).(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH,
CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG,
KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW,
MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE,
DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI
patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,
SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).**Published***With international search report.*(54) Title: METHOD FOR PREDICTION OF PREMATURE DELIVERY USING ESTETROL (E₄) AS AN INDICATOR

(57) Abstract

A method for predicting and detecting the onset of labor in a patient, which comprises analyzing a body fluid of the patient for estetrol concentration; correlating the concentration with a standard value; and relating a higher concentration of estetrol relative to the standard value as an indication of potential onset of premature delivery. The standard is usually selected from the group consisting of (1) a predetermined range of estetrol concentration for the body fluid in normal pregnant humans at a preselected time relative to normal, full-term delivery, or (2) a previously measured estetrol concentration of the same body fluid of the same pregnant human. The invention also includes a method of monitoring tocolytic therapy, which comprises determining a first concentration of estetrol in a body fluid of a pregnant patient undergoing or diagnosed as a candidate for undergoing treatment with a tocolytic agent and, based on the value of the first concentration relative to a standard, either initiating, continuing, discontinuing, or modifying the treatment.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHOD FOR PREDICTION OF PREMATURE DELIVERY USING
5 ESTETROL (E₄) AS AN INDICATOR

INTRODUCTION

Technical Field

This invention is directed to a method for prediction of termination of
10 pregnancy by premature labor resulting in premature delivery. This invention also
relates to techniques for determining when tocolytic therapy to prevent delivery
should be initiated and to what extent and duration it should continue.

Background

15 Estrogens, which are 18-carbon steroids with an aromatic A ring, a phenolic
hydroxyl group at position 3 of the A ring, and an oxygen functional group (either
hydroxyl or carbonyl) at position 17 of the D ring, produce a wide variety of effects
on specific target organs and on the body as a whole, working either alone or in
conjunction with other hormones. Most studies of estrogens have focused on
20 estradiol (sometimes referred to as E₂, which refers to the presence of two hydroxyl
groups), which has been considered to be the principal active estrogen. However,
estradiol is not a useful indicator of onset of labor in pregnant humans, as discussed
in Block *et al.*, *Am. J. Obstet. Gynecol.* 150:716-22 (1984), which flatly states that
pre-term delivery is not predicted by serum plasma estradiol (or progesterone)
25 concentration measurements.

Estetrol (E₄) is predominantly made in the fetus where its main precursor is
circulating estradiol. After reaching the fetal liver, estradiol undergoes hydroxylation
at the 15 α and 16 α positions leaving E₄. The increased solubility in body fluids of
estetrol relative to estradiol and its resulting appearance in unconjugated form in a
30 variety of body fluids makes estetrol a desirable target for analysis, once a thorough
understanding of its association with biological activity can be achieved.

Estetrol levels in plasma during normal pregnancy was studied by Tulchinsky
et al., *JCE&M*, 40: 560-567 (1975). Measurement of plasma estetrol during

pregnancy is described as useful for monitoring fetal well-being because of its production in the fetal liver. However, there are no proposals to relate estetrol concentrations to clinical situations other than fetal well-being.

Premature birth is the leading cause of infant morbidity and death in the United States and other developed countries. When a patient goes into pre-term labor, an attending physician has the option of allowing the delivery to proceed or attempting to stop uterine contractions with tocolytic agents. While many factors will affect this decision, a primary factor is the gestational age of the fetus. Tocolytic agents are generally used between 24 and 32 weeks of gestation, as the goal of therapy ideally is to prolong gestation to or beyond 32 weeks. However, a delay of even one week during this time can be significant, because of the rapid development of the fetus and the greatly improved chances for survival with each additional week of prolonged gestation.

A number of different tocolytic agents have been used for treating premature delivery. However, it has been difficult in the past to determine when therapy should properly begin or to decide when it should be decreased, increased, or halted. Some studies have indicated that the diagnosis of pre-term labor may be in error as much as 80% of the time (M. O'Driscoll, Discussion in: Anderson et al., eds., Pre-Term Labour, Proceedings of the Fifth Study Group of the Royal College of Obstetricians and Gynecologists London, Royal College of Obstetricians and Gynecologists 1977: 369-70). Excessive uterine contractibility and cervical dilation have been used in the past and are currently used to diagnose impending premature delivery; fetal breathing movements have been investigated. See Turnball, Eur. J. Obstetrics & Gynecology and Repro. Biol. 33:11-24 (1989); Anderson, Am. J. Obstetrics & Gynecology 105:1207-14 (1969). In about 30% of apparent pre-term labor cases, uterine contractions cease spontaneously without treatment (M. Wynn and A. Wynn, The Prevention of Pre-term Birth, London, Foundation for Education and Research and Child Bearing, 1977). Although labor is often diagnosed by the presence of regular uterine contractions combined with cervical dilation and effacement, many investigations have based the diagnosis of pre-term labor on contractions alone (K. Higby, et. al., *Do Tocolytic Agents Stop Pre-term Labor? A Critical and Comprehensive Review of Efficacy and Safety*, Am. J. Obstet. Gynecol., April 1993,

1247-1259). The error in diagnosis with contractions used as a sole diagnosis criteria is estimated to be from about 40 to about 70% (S.N. Caritis, et. al., *Pharmacologic Inhibition of Pre-term Labor*, Am.J. Obstet. Gynecol., 1979, 133:557-578).

Tocolytic agents are administered in order to reduce or prevent uterine
5 contractions once pre-term labor has been diagnosed. However, tocolytic agents can have adverse side-effects, so care must be taken in determining whether therapy should begin or continue. In addition, evaluation of when tocolytic therapy should be stopped is also somewhat confused. Criteria utilized include simple temporary arrest
10 of uterine contractions, no further change in cervical dilation or effacement, as well as combinations of these clinical symptoms. However, in many cases an initial arrest of uterine contractions will be followed by additional contractions once therapy is halted. At the present time there are no clinical assays for determining the extent or duration of tocolytic therapy designed to prevent uterine contractions and thus premature birth.

15 Accordingly, it is an object of this invention to establish the relationship of estetrol concentrations in various body fluids to underlying biological functions, notably premature delivery, and to provide diagnostic assays for estetrol to evaluate the existing and/or potential biological state of the patient from whom the estetrol sample has been obtained.

20 It is another object of this invention to develop a clinical assay to provide additional useful information to a physician who must decide whether to initiate, continue, decrease, increase, or halt tocolytic therapy.

It is another object of this invention to provide a simple biochemical assay that will allow an attending physician to monitor the correct beginning time for and
25 duration of tocolytic therapy.

It is a further object to provide a quantitative assay for efficacy of tocolytic treatment so that continued tocolytic treatment can be adjusted to the minimum effective pharmaceutical level.

Previous investigations by the present inventor have indicated that estriol
30 levels are predictive of premature onset of labor. See U.S. patent application serial No. 07/952,438, filed 28 September 1992. Additionally, the use of estriol measurement during labor to monitor the effectiveness of tocolytic agents was

reported by the present inventor in U.S. patent application serial No. 08/136,219, filed October 13, 1993. However, the value of estetrol in monitoring onset of premature labor or in monitoring the effectiveness of tocolytic agents during labor has not previously been established.

5

SUMMARY OF THE INVENTION

The present invention provides a method for predicting/screening and detecting the onset of labor, especially labor associated with premature delivery, in a pregnant human, which comprises analyzing a body fluid of the pregnant human for estetrol concentration; correlating the concentration with a standard value selected from the group consisting of (1) a predetermined range of estetrol concentrations for the body fluid in normal pregnant humans or (2) a previously measured estetrol concentration of the body fluid of the pregnant human; and relating a higher concentration of estetrol relative to the standard value as an indication of potential onset of premature delivery.

10
15

The invention provides a method of monitoring tocolytic therapy, which comprises measuring a first concentration of estetrol in a body fluid of a pregnant patient undergoing or diagnosed as a candidate for undergoing treatment with a tocolytic agent; correlating the concentration with a pre-determined standard estetrol concentration; and either initiating, continuing, discontinuing, or modifying the tocolytic treatment in response to the relative values of the first estetrol concentration and the standard estetrol concentration.

20

DESCRIPTION OF SPECIFIC EMBODIMENTS

The present invention provides a method for detecting the onset of labor, especially premature labor associated with delivery, in a pregnant human by simply measuring a body fluid for estetrol concentration. This method is simpler than prior techniques and provides an assay that can be carried out by a patient at home, obviating the necessity of providing samples to a professional laboratory at a location distant from the patient and the resulting delay. For example, the assay can be carried out on a single saliva sample using a simple diagnostic kit with an enzyme label.

25
30

In this invention, there are no limitations on the type of assay used to measure estetrol. Any of the current assays for estetrol can be used, as well as assays that may be developed in the future. Examples of estetrol assays are described below.

5 The assay can be carried out on any sample of body fluid, such as blood (or a blood fraction, especially serum or plasma), urine, cervical or vaginal secretions, sweat, or saliva. Estetrol is sufficiently soluble in water so that it is distributed in fluids throughout the body. Saliva is preferred for simplicity of sampling and because, unlike in urine, detection is not complicated by the presence of estrogen conjugates.

10 For *ex vivo* monitoring, a "sample" is the material being analyzed and is usually of direct biological origin, although pre-treatment may have removed some of the normal biological compounds normally associate with the analyte (such as red cells separated from plasma in a whole blood sample). Assays are preferably directed to detection to free estetrol, since conjugated estetrol has reduced biological activity. In plasma, estetrol can be detected in the free form, while most estetrol in urine is present as a conjugate. As will be clear to those familiar with steroid metabolism, an estetrol conjugate is a compound formed by formation of a covalent linkage of a non-steroidal compound to estetrol. Linkage is typically through a hydroxyl group of the steroidal ring system. The non-steroidal component can be inorganic (e.g., a sulfate group) or organic (e.g., a glucuronide group).

20 In the broader aspects of the invention, there are no limitations on the collection and handling of samples as long as consistency is maintained. With some body fluids, such as plasma, there is little diurnal variation in estetrol levels. For other fluids, notably urine, variations occur, and it is preferred to eliminate variations to the extent possible, for example by taking samples at the same time of day. However, other techniques can be utilized to ensure consistency of measurement of analytes in clinical fluids. For example, creatinine can be measured concurrently with estetrol in urine. Creatinine is produced at a constant rate in the kidneys, and measurement of creatinine concentration allows correction of volume errors in urine samples, as is well known in the art.

30 If desired (but not required in the broadest applications of this invention), and depending on the source of the fluid being tested, free estetrol can be separated from

estetrol conjugates. Techniques for such separations are known in the art. See, for example, Konbai *et al.*, *Steroids* 30:521-529 (1977), which describes such a separation as well as a radioimmunoassay useful for measuring plasma estetrol. However, these separations are generally difficult, and assays that do not require separation, either because of the use of specific antibodies or other binding compounds that differentiate between free and conjugated estetrol, or because the sample is obtained from a source containing mostly free estetrol are preferred.

The concentration of estetrol in the fluid assayed is correlated with a standard value to determine when labor is imminent. The standard is usually (1) a predetermined range of estetrol concentrations for the same body fluid in normal pregnant humans in the general population, either at the corresponding time in the pregnancy or a specific time relative to normal termination of pregnancy, or (2) a previously measured estetrol concentration of the same body fluid of the same pregnant human. A measured higher concentration of estetrol relative to the standard value is an indication of potential onset of premature delivery. The method of the invention does not require the measurement of any other substance, such as the progesterone concentration in the body fluid, or require the measurement of total estetrol production over a time interval. However, measurements of total estetrol over a given time period, such as 24 hours, can be used with urine, if desired.

As used herein "imminent" means that premature delivery is likely; it is not possible to determine precisely when delivery will occur in the absence of intervention. In some cases delivery can be delayed for several additional weeks. However, a statistically significant increase in the estetrol concentration of a body fluid gives a physician early warning of the likely onset of labor, even in the absence of clinical symptoms, so that clinical symptoms can be closely monitored and/or patient behavior modified (e.g., by avoiding extended absence from a physician's care or, in cases of greatest apparent danger, by hospitalizing the patient).

The first general standard set out above, namely a predetermined range of estetrol concentrations for the same body fluid in normal pregnant humans in general, is typically obtained by using the same assay technique that will be used in the application of the method to an individual being tested, in order to ensure the highest correlation. Sufficient measurements are made in a normal population of pregnant

women to produce a statistically significant range of normal values for the value to which a comparison will be made, which typically is at preselected time intervals during normal pregnancy. While comparison to a time immediately prior to normal delivery (38 to 40 weeks) is often used, other time periods can be used. For
5 example, estetrol levels during a given week of an individual pregnancy (i.e., that of the subject patient) can be compared to the normal range of concentrations for the same time period (e.g., the 20th week). Generally, the minimum concentration indicative of possible onset of labor is considered to be at least 1, preferably at least 2, more preferably at least 3, and most preferably at least 4, standard deviations
10 above the mean estetrol concentration determined for any given body fluid for the selected comparison, such as for a time just prior to the onset of labor for normal pregnant humans.

It will be recognized by those familiar with statistics that the number of standard deviations used as an indication of pregnancy complications will be selected
15 with an appropriate diagnosis goal in mind. For example, a range of one standard deviation above and below the mean would encompass about 68% of normal samples; that is, 32% of normal samples would be expected to fall outside the lower and upper limits set by one standard deviation from the mean (16% would thus be expected to be above the selection limit). Thus, one standard deviation above the normal mean is
20 not used for definitive analysis, as it would include too many false positives. However, one standard deviation is appropriate for an assay that is desired to sweep in for further evaluation all possible candidates who might be predisposed toward premature delivery, or this limit can be selected for patients known to have normal or low estetrol values and relatively little variation between samples. One standard
25 deviation can also be selected for a patient known to have problems with premature delivery in order to determine when to monitor the patient more closely under controlled conditions (such as by having a patient admitted to a hospital for constant monitoring). Two standard deviations from the mean would encompass about 95% of normal samples; three standard deviations, about 99%; four standard deviations,
30 more than 99%. These levels are more appropriate generally, especially for patients whose levels of estetrol are known to be normal or slightly above normal or to vary from sample to sample, as well as for assays with a high coefficient of variance. In a

preferred embodiment, estetrol levels that are sustained at or above a preselected elevated threshold (e.g., over at least 12 hours, preferably at least 24 hours, more preferably at least 72 hours) are preferred as an indication of likely onset of labor.

It is not necessary to express the lower limit of the indication of labor (upper
5 limit of the normal range) in standard deviations. Any other system that can be used to provide a statistically significant indication of probable onset of labor can be used. For example, the limit can be set to be a concentration that is at least as high as the 95th percentile concentration for normal patients for the same body fluid for a normal pregnancy. In many cases, it is preferred to select a normal level from the 38-42
10 week period for normal pregnancies, preferably at 40 weeks, and to monitor the concentration beginning at 30 weeks or earlier.

Because of the many different possible clinical goals, the actual estetrol level indicative of probable onset of premature delivery is best selected by the attending physician after collecting data from several samples from the patient during the initial
15 portion of the pregnancy and taking into consideration the time at which the measurement is being made. For example, in a normal pregnancy at week 30, the change expected in the estetrol concentration prior to the onset of labor is smaller than 2 standard deviations from the mean concentration of estetrol at 30 weeks. Thus, while assays in the first portion of a pregnancy (prior to 30 weeks) might use 3
20 or 4 standard deviations as an indication of onset of labor, two, one and a half, or even one standard deviation would be more appropriate in the later portion of a pregnancy (e.g., after 30 weeks) depending on the condition of the patient, other clinical indications in the mother known to the attending physician, and the health of the fetus. Of course, it is the earlier stages of a pregnancy that require greater
25 attention to avoiding premature delivery, because of the lack of fetal development at these stages and the high risk of infant death post partum. Premature delivery is thus considered to be any labor prior to end of the normal 40 week term of pregnancy, preferably prior to the beginning of the thirty-eighth week after conception. The method of the invention is preferably used for pregnancies during weeks 20 to 36,
30 when prolonging pregnancy for even a short time is most efficacious in reducing the effects of premature birth. However, the assay, particularly when used to detect rate of increase, is still applicable for pregnancies terminated by labor and delivery after

the end of 40 weeks, and measurements made during this time period are also considered to fall within the broadest scope of the invention. When applied to weeks 38 and higher, the invention is normally practiced using the "self-comparison" method discussed in more detail below; i.e., by comparing the measurement at a
5 given time with a measurement made earlier with the same patient.

In a similar manner, subject to the same constraints discussed above, an assay concentration of at least 1, preferably at least 2, more preferably at least 3, and most preferably at least 4, standard deviations above the mean normal concentration for the same stage of pregnancy can also be used as an indication of an abnormal pregnancy
10 and thus as an indication of possible onset of labor, although the probability is lower if the measured level does not reach the levels considered normal for weeks 38-42. Standard values will vary with the specific body fluid whose concentration is being measured and with the specific assay being used (although to a lesser extent).

As an alternative to comparing estetrol concentrations to those present in a
15 normal population, a previously measured estetrol concentration of the same body fluid of the same pregnant human can be used as a standard for comparison. In this case, what is being determined is usually the rate of increase in estetrol concentration in the fluid being tested. A positive assay (i.e., indication of imminent onset of labor) is considered to be present when the measured concentration exceeds a
20 previously measured estetrol concentration made in the same body fluid in the same pregnant human female by 50%, preferably 75%, more preferably 100%, within one week. Again the selection of a particular rate of increase to label as the lower limit of labor onset is best selected by the attending physician for the particular reason desired. For example a screening test that is intended to collect potential problem
25 patients into the hospital for further observation and study could select the 50% increase as its limit in order to avoid false negative results, while accepting the problems caused by including a relatively large number of false positives. Higher percentage increases as the minimum positive indication are more acceptable for home assays and the like, in the same manner as described above for standard
30 deviations from the normal population mean. Increases in estetrol concentration that meet the standards of this paragraph and additionally reach levels previously indicated

to be indicative of the onset of labor in normal populations of patients are particularly likely to indicate imminent onset of labor.

It will be recognized by those skilled in clinical analysis that assays for a given analyte, including this assay for estetrol, are not expected to be obtained or to be interpreted by an attending physician in the absence of additional information. Additionally, the results of any assay are best considered to be indicative of the probability of the presence of a clinical condition rather than as absolute proof. The same situation exists for the present invention. Nevertheless, an indication of increased probability of onset of labor is clinically useful information and can be used by a skilled medical practitioner in combination with other information to care for patients in a more informed manner than would be possible if the information were not available.

Standard enzyme-linked immunoassay techniques can be used for assaying estetrol. Antibody production for use in such assays and the assays themselves are conventional and are not described here in detail. These techniques are well known in the literature and are exemplified by the publication Antibodies: A Laboratory Manual (1988) eds. Harlow and Lane, Cold Spring Harbor Laboratories Press, and U.S. Patent Nos. 4,381,292, 4,451,570, and 4,618,577. For an example of production of antibodies specific for estradiol, see Lasley *et al.*, *Fertility and Sterility* (1985) 43:861-867, and Munro *et al.*, Abstract, Society for Gynecologic Investigation, San Diego, March 1989. The same techniques can be used to produce antibodies to estetrol. A brief discussion of general techniques for the production of antibodies specific for steroids is included for those who may be unfamiliar with the process.

An animal is injected with a composition containing estetrol covalently attached to an immunogen, usually a protein, prepared as described above. Multiple injections or the use of an adjuvant will ensure maximum stimulation of the immune system and production of antibodies. If polyclonal antibodies are desired, they can be prepared by simply collecting blood from the immunized animal and separating the antibodies from other blood components by standard techniques. To obtain monoclonal antibodies, the spleen or lymphocytes from the immunized animal are removed and immortalized or used to prepare hybridomas by cell-fusion methods

known to those skilled in the art. Antibodies secreted by the immortalized cells are screened to determine the clones that secrete antibodies of the desired specificity. For monoclonal anti-estetrol antibodies, the antibodies must bind to estetrol. Cells producing antibodies of the desired specificity are selected, cloned, and grown to
5 produce the desired monoclonal antibodies.

Antibody can be attached to a solid surface for use in an assay of the invention using known techniques for attaching protein material to solid support materials. The solid support can include plastic surfaces of test tubes or microtiter plates, polymeric beads, dip sticks, or filter materials. The attachment methods
10 include non-specific adsorption of the protein to the support and covalent attachment of the protein, typically through a free amino group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group.

By detecting the probable onset of premature delivery as described herein, a physician will be able to use existing techniques for delaying labor to avoid
15 premature delivery and the resulting high risk of infant death. In this regard, the present invention provides a method for monitoring the efficacy of tocolytic treatments that reduce or eliminate uterine contraction in order to delay the onset of labor, especially pre-term labor, in a pregnant human. Monitoring estetrol concentrations in a body fluid before or during treatment with a tocolytic agent
20 allows a physician to reach better decisions on whether to begin or continue the tocolytic treatment or whether the treatment should be discontinued or modified.

This method is quantitative and allows a physician to adjust the nature of the treatment as well as to determine when it should begin or end. In summary, the method involves measuring a first concentration of estetrol in a body fluid of a
25 pregnant patient undergoing, or diagnosed as a candidate for undergoing, treatment with a tocolytic agent. This first concentration is compared to a standard, and various actions are taken depending on the relative value of the measured concentration and the standard, as well as on the history of the patient prior to the measurement in question. In general, a measured estetrol concentration above the
30 standard value is an indication that tocolytic treatment should be initiated or, if already initiated, should be continued or increased in intensity. In a similar manner, if the estetrol concentration is below the standard value, tocolytic treatment will not

be initiated or, if already initiated, will be decreased or halted depending on the measured concentration relative to the standard. Because estetrol measurement is straight-forward and can be carried out at the bedside, an attending physician can obtain quantitative results very rapidly, which is of great assistance in reaching a clinical decision. The assay is the same as that described above for use in detecting potential onset of labor.

The concentration of estetrol in the fluid assayed is correlated with a standard value to determine when to initiate, increase, decrease, cease, or otherwise modify the tocolytic treatment. The standard is usually (1) a predetermined range of estetrol concentrations for the same body fluid in normal pregnant humans in the general population, either at the corresponding time in the pregnancy or a specific time relative to normal termination of pregnancy, or (2) a previously measured estetrol concentration of the same body fluid of the same pregnant human. A measured higher concentration of estetrol relative to the standard value is an indication of potential onset of pre-term labor and therefore an indication that tocolytic treatment should be initiated or, if already initiated, should be increased in intensity. The method of the invention does not require the measurement of any other substance, such as the progesterone concentration in the body fluid, or require the measurement of total estetrol production over a time interval. However, measurements of total estetrol over a given time period, such as 24 hours, can be used with urine, if desired, and other substances important to fetal or maternal well being, such as progesterone, can be concurrently measured if desired.

Prior to the investigations in the laboratory of the present inventor reported in the Background section of this specification, there was no predictive test for pre-term labor or technique for monitoring tocolytic treatment. Accordingly, it is difficult to predict the variations of treatment that may arise among physicians and other care providers now that the various diagnostic tests based on estetrol concentration have been developed. A single elevated sample in a high risk patient at an early gestational age would probably be adequate for most physicians to initiate tocolytic therapy. However, other physicians may choose to wait for other clinical criteria, such as uterine contractions and cervical change, and/or for a recurrence of an elevated estetrol level.

The attending physician will most likely determine when to begin tocolytics by considering the estetrol level among other factors, such as the physical condition, size and weight of the patient, the severity of uterine contractions, and the extent of cervical dilation.

5 Most of the discussion above addresses the issue of initiation of tocolytic treatment. However, since increased estetrol concentrations above normal values continue to be an indication of likely re-initiation of premature labor even after an initial tocolytic treatment, continuing to monitor estetrol concentrations allows a physician better control over further tocolytic treatment. At the beginning of
10 tocolytic treatment, estretrol concentrations can preferably be monitored at daily intervals for at least one week, then at weekly intervals, depending upon results. For example, if estetrol measurements are continued during treatment and a decrease is seen to normal estetrol levels, tocolytic treatment can be halted. On the other hand, if uterine contractions cease after tocolytic treatment but the estetrol levels remain
15 high, then there is a high probability that labor will begin again if tocolytic treatments are halted. Accordingly, tocolytic treatments should be continued, if appropriate when considered in combination with other clinical symptoms. Furthermore the intensity of the tocolytic treatment (see below for specific treatments) can be either increased or decreased depending on the value of the estetrol concentration relative to
20 the standard value. If the measured value is significantly higher than the standard and shows no sign of decreasing, then the intensity of the tocolytic treatments can be increased. Conversely, if the estetrol levels remain higher than normal, but have been reduced somewhat by the initial tocolytic treatment, then either the initial treatment can be continued at its initial intensity or the intensity of the treatment can
25 be reduced, with continuous monitoring of the effect of the treatment of estetrol concentration.

The situation regarding continued tocolytic treatment as indicated by the estetrol level is somewhat more complicated than the initial initiation of tocolytic treatment. While a physician may halt tocolytic treatment when the estetrol
30 concentration drops below the standard chosen as an indication of initial treatment, such patients should be carefully monitored as they are predisposed to re-initiation of pre-term labor. It may be more desirable, depending on the specific clinical

symptoms that accompany the tocolytic treatment, to continue tocolytic treatment until the measured value reaches the mean standard value or even some value below the mean to provide better control of labor re-initiation.

It will be recognized by those skilled in clinical analysis that assays for a given analyte, including this assay for estetrol, and the resulting modification of treatment, such as this tocolytic treatment, are not expected to be obtained or to be interpreted by an attending physician in the absence of additional information. Additionally, the results of any assay are best considered to be indicative of the probability of the presence of a clinical condition rather than as absolute proof. The same situation exists for the present invention. Nevertheless, an indication of increased probability of onset of labor is clinically useful information and can be used by a skilled medical practitioner in combination with other information to care for patients in a more informed manner than would be possible if the information were not available.

15

Specific Tocolytic Treatments

The invention can be carried out with any tocolytic treatment, since it now appears that all such treatments are associated with modifications in the estetrol level in the body fluids of the mother. A number of different classes of drugs that inhibit uterine concentration have been suggested and are discussed below by drug class. However, the invention is not limited to the named tocolytic treatments, either individually or by class.

β -Adrenergic Agonists

Isoxsuprine was the first β -sympathomimetic agent used to treat premature delivery, in 1961. Since then the functionally related compounds orciprenaline, metaproterenol, salbutamol, albuterol, nyldrin, terbutaline, ritodrine, hexoprenaline, and fenoterol have been used.

Like the endogenous catecholamines epinephrine and norepinephrine, these drugs stimulate β -adrenergic receptors in the uterus and other organs. There are two types of β -adrenergic receptors in humans. β_1 -Adrenergic receptors predominate in the heart, small intestine, and adipose tissue; β_2 -adrenergic receptors are found in

30

smooth muscle of the uterus, blood vessels, diaphragm, and bronchioles. β -Adrenergic agonists affect smooth muscle cells through membrane-mediated binding to β -adrenergic receptors that activates adenylate cyclase. This leads to an increase in intracellular cyclic adenosine monophosphate, which, in turn, initiates a series of reactions resulting in reduced intracellular levels of calcium and reduced sensitivity of the myosin-actin contractile unit to available calcium. The inhibitory effect on the uterus occurs even in the presence of oxytocin. Continued exposure to β -adrenergic agonists leads to desensitization. With prolonged exposure, the number of β -adrenergic receptors decreases (down-regulation), further reducing the effect of the drug.

β -Adrenergic agents cause many unwanted effects because β -adrenergic receptors are present in multiple organ systems. The cardiovascular system is most often involved. However, effects are also seen on the pancreas, kidney, gastrointestinal tract, and liver. The most frequently observed maternal symptoms are nausea, vomiting, tremor, and palpitations. Women also experience headache, thirst, restlessness, and chest pain.

The most common effects on the cardiovascular system are increases in heart rate, systolic blood pressure, pulse pressure, stroke volume, and cardiac output. There is a concomitant decrease in diastolic pressure and peripheral vascular resistance. Cardiac output can increase up to 60% over baseline levels. Mean arterial pressure does not change significantly. Cardiac arrhythmias have been reported. The most common is supraventricular tachycardia; the arrhythmias include atrial fibrillation, premature atrial contractions, and ventricular ectopy.

Increased heart rate and myocardial contractility can predispose to myocardial ischemia. Coronary artery perfusion is decreased as a secondary result of a decrease in diastolic blood pressure and diastolic filling time. These effects can cause micronecrosis of the myocardium. The electrocardiogram changes most frequently observed are transient ST segment depression and inverted T waves. These changes, which may be present in up to 76% of women treated with ritodrine, are often not associate with symptoms. They may be caused by relative hypo-perfusion of the subendocardium. Others, who found no changes in cardiac enzyme levels, concluded that the electrocardiogram findings do not indicate significant myocardial damage.

The electrocardiogram findings, which usually resolve with discontinuation of therapy, may not be due to myocardial ischemia, but rather to electrolyte imbalances.

Pulmonary edema occurs in up to 5% of patients treated with β -sympathomimetics. Pulmonary edema occurs with and without concurrent
5 glucocorticoid therapy. Many cases are secondary effects of fluid overload resulting from the antidiuretic effect of high doses of β -sympathomimetics. Fluid overload can also be a secondary result of excessive administration of intravenous fluids.

Plasma renin and arginine vasopressin are increased during infusion of β -adrenergic agonists. This increase is associated with sodium and water retention,
10 which predisposes to pulmonary edema. Pulmonary edema is more common in twin gestations. Infection may also play a role in the development of this complication. In the absence of underlying disease, most cases of pulmonary edema can be attributed to intravenous fluids and to ignoring signs of fluid overload.

β -Sympathomimetics increase maternal blood glucose about 40% with a
15 concurrent increase in insulin secretion. The rise in glucose levels is even more pronounced in diabetes, probably because stimulation of glucagon secretion results in gluconeogenesis and glycogenolysis. Insulin levels rise as a result of hyperglycemia and also from direct stimulation of β -adrenergic receptors in the maternal pancreas. Insulin release precedes the onset of hyperglycemia. The effect is heightened by
20 concomitant administration of corticosteroids. β -Adrenergic agonists also include lipolysis, which increases acidic metabolites and can lead to severe metabolic acidosis in diabetic patients.

Serum potassium concentrations decrease rapidly at initiation of treatment with β -sympathomimetics. The potassium concentration is usually 0.6 to 1.5 mEq below
25 pretreatment levels. This decrease in serum levels is probably due to a net flux of potassium from the extracellular to the intracellular space. The hypokalemia is transient; replacement therapy is not indicated. Levels normalize within 24 hours of initiation of tocolysis.

Other effects reported include maternal transaminase elevations, paralytic
30 ileus, myotonic muscular dystrophy, postpartum cardiomyopathy, respiratory arrest caused by muscle weakness in a patient with myasthenia gravis, acute cutaneous vasculitis, allergic dermatitis, hypertensive crisis, cardiac failure, agranulocytosis,

cerebral ischemia, second-degree heart block, massive vulvar edema, adult respiratory distress syndrome, severe hemolytic anemia, and maternal death.

β -Sympathomimetics rapidly cross the placenta. Stimulation of β -adrenergic receptors in the fetus probably evokes the same responses as in the mother.

- 5 Cardiovascular effects include fetal tachycardia, increased cardiac output and redistribution of fetal blood flow, increased thickness of the fetal ventricular septum, neonatal supraventricular tachycardia, myocardial ischemia, myocardial necrosis, hydrops, and hypoglycemia and hyperinsulinemia in the neonate.

10 Studies examining alterations in uteroplacental blood flow have been conflicting. Some report decreased blood flow, others increased uteroplacental blood flow, and still others no significant change. Alterations in blood flow are not associated with significant changes in fetal hemodynamics. The differences may be attributed to the duration of infusion, the drug used, concurrent use of other medications, and the method used to measure uteroplacental blood flow.

15

Magnesium Sulfate

Magnesium inhibits myometrial activity *in vitro* and *in vivo*. Magnesium inhibits uterine contractions induced by calcium and transiently inhibits further calcium response.

20 The mechanism by which magnesium sulfate exerts its tocolytic effect is unknown. Presumably, myometrial contractility is depressed by modulating calcium uptake, binding, and distribution in smooth muscle cells, take, binding, and distribution in smooth muscle cells. In high concentrations magnesium blocks calcium influx by competing for calcium binding sites on the cellular membrane.

25 Magnesium activates adenylate cyclase and increases cyclic adenosine monophosphate, thus reducing intracellular calcium. Serum concentrations of 4 to 8 mEq/L appear to be necessary for reduction of myometrial activity.

30 Dual-agent tocolysis after failure of single-agent therapy has also been reported in the scientific literature. Twenty-three patients were treated with a combination of magnesium sulfate and ritodrine or terbutaline. Delivery was delayed for ≥ 48 hours or more in 60.9% of patients, but pulmonary edema developed in 22% of the patients.

When magnesium sulfate therapy is maintained in the nontoxic range, maternal side effects are few. Nausea, vomiting, ileus, visual blurring, diplopia, headaches, weakness, lethargy, shortness of breath, pulmonary edema, alterations in calcium metabolism, and urinary retention have been reported. Hypermagnesemia
5 can occur in the presence of impaired renal function. Excessive levels of serum magnesium have been associated with respiratory depression, subendocardial ischemia, cardiac arrest and death.

Magnesium sulfate crosses the placenta. Fetal plasma concentrations are comparable to those in the mother. Neonatal hypotonia and drowsiness have been
10 reported. Bony abnormalities and congenital rickets in the newborn have been associated with magnesium sulfate infusion for tocolysis.

Oxytocin Antagonists

Labor, term or pre-term, is associated with an increase in myometrial
15 oxytocin receptors. Myometrial oxytocin receptors increase twelve-fold at term, compared with those at 13 to 17 weeks of gestation, and also increase in women who are delivered pre-term. Theoretically, oxytocin antagonists might provide effective tocolysis, because systemic side effects would be minimal because of organ specificity.

20 Several studies describe the effects of oxytocin antagonists *in vitro*. One investigated the ability of 1-deamino-2-D-Tyr(0-ethyl)⁴-Thr⁸-Orn-oxytocin to inhibit binding of oxytocin in decidual and myometrial membranes of the rat, guinea pig, and human. Decidua and myometrium of all three species bound tritium-labeled oxytocin with high affinity, and 1-deamino-2-D-Tyr(0-ethyl)⁴-Thr⁸-Orn-oxytocin
25 completely displaced labeled oxytocin from binding sites in all tissues. Another examined a synthetic oxytocin antagonist [β -mercapto- β,β -cyclopentamethylene propionic acid, D-Trp²-Ile⁴-Arg⁸]-vasopressin. This compound inhibited oxytocin-induced contractions in the nonpregnant rat uterus, *in vitro* and *in vivo*. It also inhibited milk letdown in the lactating rat, disrupted labor in the rat, and inhibited
30 the *in vitro* response to oxytocin of myometrium obtained from women. Four oxytocin analogs, 1-deamino-2-D-Tyr[0-ethyl]⁴-Val⁸-Orn-vasotocin, 1-deamino-2-D-Tyr[0-ethyl]⁴-Thr⁸-Orn-vasotocin, 1-deamino-2-L-Tyr[0-ethyl]⁴-Thr⁸-Orn-vasotocin,

and 1-deamino-2-D-Trp⁴-Thr⁸-D-Arg-vasotocin, displaced oxytocin and arginine vasopressin in myometrial membrane preparations from pregnant women at term.

Two reports describe the use of oxytocin antagonists in women in pre-term labor. The first used 1-deamino-2-D-Tyr[0-ethyl]⁴-Thr⁸-Orn-oxytocin in 13 patients. 5 Uterine activity was inhibited in all patients. However, 10 patients received subsequent therapy with β -sympathomimetics, and three (23%) were delivered pre-term. A second study used intravenous infusions of 1-deamino-2-D-Tyr[0-ethyl]⁴-Thr⁸-Orn-oxytocin in 12 patients in premature delivery. All patients were initially placed at bed rest for 2 hours and were treated if contractions persisted. Complete tocolysis 10 was noted in six patients, partial tocolysis in three patients, and no tocolytic effect in three patients. The three patients in whom there was no effect were less than 28 weeks pregnant and were subsequently treated with ritodrine. Ultimately, 7 of 12 patients were delivered pre-term. No maternal side effects, fetal heart rate abnormalities, or complications with breast-feeding were attributable to treatment. 15 No comments were made regarding neonatal morbidity or mortality.

Prostaglandin Inhibitors

Local prostaglandin production probably plays a role in cervical ripening and may modulate uterine activity in labor. Many birthing centers use prostaglandin E₂ 20 gel for cervical ripening. Both prostaglandin E₂ and prostaglandin F_{2 α} are used for induction of labor in the second trimester of pregnancy.

Prostaglandins exhibit uterine effects in two ways. First, they enhance production of myometrial gap junctions. Second, prostaglandin F_{2 α} stimulates the influx of intracellular calcium and the release of calcium from the sarcoplasmic 25 reticulum. This increase in intracellular calcium leads to activation of myosin light chain kinase and subsequent muscle contraction. Elevated levels of prostaglandins in plasma and amniotic fluid have been demonstrated during normal human parturition. Levels are low or absent in serum and amniotic fluid of patients not in labor at all states of pregnancy. Prostaglandin metabolites are significantly reduced in patients 30 treated with indomethacin. They are also significantly higher in patients who are delivered pre-term than in patients with prolonged gestation.³²

All prostaglandin synthetase inhibitors act by inhibiting the enzyme cyclooxygenase. This enzyme is found throughout the body and in high concentrations in the myometrium. Cyclooxygenase converts arachidonic acid into the first prostaglandin intermediate prostaglandin G₂. All subsequent prostaglandins are derived from this initial step. Aspirin causes irreversible inhibition of this enzyme by acetylation. Indomethacin competes with arachidonic acid for cyclooxygenase. Therefore it does not disrupt the enzyme. When indomethacin levels decrease, enzyme activity resumes. These drugs have anti-inflammatory, antipyretic, and analgesic properties. They also suppress formation of prostacyclin and thromboxane A₂. Indomethacin, naproxen, and fenoprofen are more effective than aspirin as inhibitors of prostaglandin synthesis.

Nonsteroidal anti-inflammatory drugs differ in chemical structures, mechanisms of action, and side effects. Therefore one cannot assume that an effect observed with a particular agent will be found with another. These drugs effectively inhibit contractility of the pregnant and nonpregnant myometrium. They are more effective than the β -sympathomimetics. There has been no report of suppression of uterine contractions with β -adrenergic agonists after failed treatment with a prostaglandin inhibitor; but several studies show the opposite.

Interest in prostaglandin inhibitors began in 1973. A retrospective study showed that patients taking high-dose salicylates during pregnancy had significant increases in mean length of gestation, frequency of post-maturity, and mean duration of spontaneous labor. In a second study patients taking long-term salicylates during pregnancy had a higher incidence of gestation extending beyond 42 weeks. Another study demonstrated that administration of oral aspirin or indomethacin prolonged the injection-to-abortion interval in patients undergoing midtrimester abortion with hypertonic saline solution. Finally, low doses of aspirin prolonged the injection-to-abortion interval in nulliparous patients undergoing midtrimester abortion with hyperosmolar urea and continuous oxytocin infusion.

The first report of the use of these drugs to stop premature delivery was published in 1974. Treatment of 50 patients in premature delivery with indomethacin delayed delivery >7 days in 40 patients (80%). Numerous subsequent studies have

attempted to evaluate the efficacy of prostaglandin inhibitors in treating premature delivery.

Prostaglandin inhibitors are not associated with serious adverse effects on mother or fetus. There were no major problems in the newborns of 297 women
5 treated with indomethacin.

These compounds differ in chemical structures, mechanisms of action, and side effects. Common adverse effects include nausea, vomiting, diarrhea, heartburn, headache, dizziness, and allergic rash. More serious toxicity is manifested by thrombocytopenia, peptic ulceration, bleeding, and serious allergic reactions. In
10 addition, prostaglandin inhibitors may mask signs of infection.

The main concern with this class of drugs is the potential for adverse effects on the fetus, particularly premature closure of the ductus arteriosus. Indomethacin is used to treat persistent patency of the ductus arteriosus in the pre-term neonate. Clinical response in the pre-term neonate is variable and not related to serum
15 indomethacin concentration. Most studies demonstrate resistance of the ductus to closure at earlier gestational ages. Prostaglandin inhibitors cause constriction of the fetal ductus arteriosus in utero. The constriction is transient and usually abates after cessation of the drug. However, prolonged exposure to indomethacin may lead to persistent pulmonary hypertension and tricuspid insufficiency in the neonate.

20 Other fetal complications include impaired renal function with resultant oligohydramnios. Indomethacin has also been used to treat polyhydramnios and normalize amniotic fluid volume. This drug may be especially useful for treating pre-term labor in patients with polyhydramnios. There is little evidence that indomethacin causes permanent renal impairment in the neonate; one case report
25 documented a monozygotic twin gestation with polyhydramnios in which the mother was treated with indomethacin and the fetus had renal digenesis.

Calcium Channel Blockers

Calcium channel blockers inhibit spontaneous myometrial contractions and
30 suppress prostaglandin- and oxytocin-induced uterine contractions *in vitro* and *in vivo*. The main site of action is the cell membrane, where influx of extracellular calcium

through voltage-dependent calcium channels is inhibited. Verapamil, but not nifedipine, impairs atrioventricular conduction and can cause cardiac dysfunction.

The use of verapamil for treating pre-term labor was first reported in 1972. Effectiveness of treatment could not be shown because dosage was limited after cardiovascular side effects. The first study using nifedipine to treat premature delivery was reported in 1977. Ten patients in pre-term labor were treated. Labor stopped in all patients. In a similar study of 20 patients, 15 had delivery delayed for >3 days. A subsequent study documented delay of delivery in eight patients with chronic hypertension, until after 38 weeks of gestation. Mean gestational age at entry was 30 weeks. The patients became normotensive during therapy.

Delivery was delayed for >48 hours in 9 of 13 patients treated with nifedipine. Ghirardini (1991) reported successful treatment of eight women in premature delivery. All were delivered after 38 weeks' gestation. In another study uterine contractions were inhibited in 16 of 22 patients in pre-term labor treated with nifedipine; 13 experienced undesirable side effects.

Two prospective, randomized studies compared nifedipine with ritodrine. The first randomly allocated 20 women to ritodrine, 20 women to nifedipine, and 20 women to no treatment. Success was defined as delay of delivery for 48 hours. Seventy-five percent success was achieved in the nifedipine group, compared with 45% in the ritodrine group and 29% in the placebo group. This study has been criticized for possible selection bias, poor reporting of side effects, and the fact that 25% of the nifedipine group were subsequently treated with ritodrine.

A recent study randomized 33 patients to ritodrine and 33 patients to nifedipine. Delivery was postponed for 48 hours in 84% of the nifedipine group and 72% of the ritodrine group. Delivery was delayed for 7 days in 70% of women treated with nifedipine and 52% of those treated with ritodrine. Maternal side effects were more common in patients treated with ritodrine ($p < 0.01$). Fetal and neonatal outcomes were similar in the two groups.

Calcium channel blockers produce vasodilation and decrease peripheral vascular resistance. Transient facial flushing is the most common side effect, but then can also cause nausea and headache. Maternal side effects appear to be less than with the β -sympathomimetics. Nifedipine potentiates the toxicity of magnesium

sulfate by causing neuromuscular blockade. It also causes maternal hepatotoxicity. Although no serious fetal or neonatal side effects have been reported, these drugs may diminish uteroplacental blood flow.

In addition to the individual treatments discussed above, tocolytic treatments
5 of the inventions can also involve combinations of the individual treatments listed above or other treatments not listed here.

Intensity of a given tocolytic treatment will generally be correlated to the concentration of the drug being administered, the duration of administration, or the frequency of administration. However, a change in intensity can also refer to a
10 change in the type of treatment from one generally considered less effective but with fewer side effects to one which is more potent but which has potentially greater side effects.

With regard to the side effects of the various treatments above, it should be recognized that this specification is not intended to recommend any particular
15 treatment. That decision should be made by the attending physician, who will generally make a decision based on both the potency of the drug being administered as a tocolytic and on the potential side effects using both the results of estetrol monitoring and other clinical signs.

By detecting the probable onset of premature delivery and monitoring tocolytic
20 treatment as described herein, a physician will be able to use existing techniques for delaying labor to avoid premature delivery and the resulting high risk of infant death.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto
25 without departing from the spirit or scope of the appended claims.

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

WHAT IS CLAIMED IS:

1. A method for detecting the imminent onset of pre-term labor in a pregnant human at 36 weeks gestation or earlier, which comprises:
 - 5 analyzing a body fluid of said pregnant human for estetrol concentration;
correlating said concentration with a standard value selected from the group consisting of
 - (1) a predetermined range of estetrol concentrations for said body fluid in normal pregnant humans and
 - 10 (2) a previously measured estetrol concentration of said body fluid of said pregnant human; and
relating a higher concentration of estetrol relative to said standard value as an indication of potential onset of labor, wherein said relating does not consider progesterone concentration in said body fluid.
- 15 2. The method of Claim 1, wherein said body fluid is saliva, plasma, serum, urine, cervical or vaginal secretion, or sweat.
- 20 3. The method of Claim 1, wherein said concentration exceeds a previously measured estetrol concentration made in said body fluid in said pregnant human within one week by 50%.
- 25 4. The method of Claim 1, wherein said concentration is at least as high as the 95th percentile concentration for said body fluid for a normal pregnancy at 40 weeks and said concentration is measured at 30 weeks or earlier.
5. The method of Claim 1, wherein said analyzing comprises a non-instrumented enzyme immunoassay for estetrol.
- 30 6. The method of Claim 5, wherein said assay produces a color change at a minimum concentration considered to be indicative of imminent labor.

7. The method of Claim 1, wherein said analyzing detects only unconjugated estetrol.

8. The method of Claim 1, wherein said higher concentration of estetrol is
5 sustained for at least 12 hours.

9. A method of monitoring tocolytic therapy, which comprises:

measuring a first concentration of estetrol in a body fluid of a pregnant patient
undergoing or diagnosed as a candidate for undergoing treatment with a tocolytic
10 agent; correlating said first concentration with a predetermined standard
estetrol value; and

based on said first concentration and its correlation to said predetermined
standard estetrol value, either initiating, continuing, discontinuing, or modifying said
tocolytic treatment.

15

10. The method of Claim 9, wherein said correlating comprises comparing said
concentration with a standard value selected from the group consisting of

(1) a predetermined range of estetrol concentrations for said body fluid in normal
pregnant humans or

20 (2) a previously measured estetrol concentration of said body fluid of said
pregnant human.

11. The method of Claim 9, wherein a higher concentration of estetrol relative to
said standard value is utilized as an indication of initiation, continuation, or increase
25 of intensity of said tocolytic treatment.

12. The method of Claim 9, wherein a concentration of estetrol less than or equivalent to said standard value is utilized as an indication of cessation or decrease of said tocolytic treatment.
- 5 13. The method of Claim 9, wherein said first estetrol concentration is higher than said standard and said tocolytic treatment is initiated, continued, or increased and said estetrol concentration is measured over time until said concentration reaches a predetermined second estetrol concentration lower than said standard.
- 10 14. The method of Claim 9, wherein said determining is carried out on a sample of a body fluid of said patient.
15. The method of Claim 14, wherein said body fluid is saliva, plasma, serum, urine, cervical or vaginal secretion, or sweat.
- 15 16. The method of Claim 14, wherein when said method is carried out prior to tocolytic treatment and said concentration exceeds a previously measured estetrol concentration made in said body fluid in said pregnant human within one week by 50%, tocolytic treatment is initiated.
- 20 17. The method of Claim 9, wherein said method is carried out prior to tocolytic treatment and said concentration is at least as high as the 95th percentile concentration for said body fluid for a normal pregnancy at 40 weeks and said concentration is measured at 30 weeks or earlier, tocolytic treatment is initiated.

18. The method of Claim 9, wherein said method detects only unconjugated
estetrol.
19. The method of Claim 9, wherein said method is carried out after initiating
5 tocolytic treatment and tocolytic treatment is halted when said concentration reaches a
measurement value no higher than 1 standard deviation above said standard value.
20. The method of Claim 9, wherein said method is carried out after initiating
tocolytic treatment and tocolytic treatment is halted when said concentration reaches a
10 measurement value no higher than 1 standard deviation below said standard value.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/03442

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(6) : A61B 17/42; G01N 33/50, 33/53, 33/74
 US CL : 435/7.9; 436/510, 65; 600/33
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 435/7.9, 7.93; 436/510, 65, 127, 131, 814; 600/33

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 APS, DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,096,830 (SENYEI et al) 17 March 1992, see entire document.	1-20
Y	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, Volume 40, Number 4, issued 1975, D. Tulchinsky et al, "Plasma Estetrol as an Index of Fetal Well-being", pages 560-567, see entire document, especially pages 561 and 563.	1-20
Y	JOURNAL OF CHROMATOGRAPHY, Volume 568, issued 1991, J. Noma et al, "Automated Direct High-Performance Liquid Chromatographic Assay for Estetrol, Estriol, Cortisone and Cortisol in Serum and Amniotic Fluid", pages 35-44, see entire document, especially page 39, Table III.	1-20

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search: 17 JUNE 1995
 Date of mailing of the international search report: 10 JUL 1995

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231
 Facsimile No. (703) 305-3230

Authorized officer: *D. Freese*
 JAMES L. GRUN, PH.D.
 Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/03442

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,081,013 (ROVELLI ET AL) 14 January 1992, see entire document, especially column 4.	5-6, 9-20
Y	H.W. TAEUSCH ET AL, "SCHAFFER AND AVERY'S DISEASES OF THE NEWBORN", published 1991 by W.B. SAUNDERS CO. (Philadelphia), see pages 87-92, especially page 92.	9-20
Y	J.R. SCOTT ET AL, "DANFORTH'S OBSTETRICS AND GYNECOLOGY", published 1990 by J. B. LIPPINCOTT CO. (Philadelphia), see pages 335-351, especially page 344, Table 17-4.	9-20
A	J.D. WILSON, "WILLIAMS TEXTBOOK OF ENDOCRINOLOGY", published 1985 by W.B. SAUNDERS CO. (Philadelphia), see pages 422-437.	1-20
A	BRITISH MEDICAL JOURNAL, Volume 294, issued 31 January 1987, J. Darne et al, "Increased Saliva Oestriol to Progesterone Ratio Before Idiopathic Preterm Delivery: A Possible Predictor for Preterm Labour?", pages 270-272, see entire document.	1-20
A, P	US, A, 5,370,135 (DULLIEN) 06 December 1994, see entire document.	1-20
A	US, A, 5,028,535 (BUECHLER ET AL) 02 July 1991, see entire document.	5-6